Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-25-000479·BIOTECHNOLOGY VALUE FUND L P
Schedule 13G ownership disclosure
Forte Biosciences Inc
Common Stock, $0.001 par value · CUSIP: 34962G208
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 338,860.00 · Class: 5.3%
- BVF I GP LLC
Shares: 338,860.00 · Class: 5.3%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 262,365.00 · Class: 4.1%
- BVF II GP LLC
Shares: 262,365.00 · Class: 4.1%
- Biotechnology Value Trading Fund OS LP
Shares: 30,882.00 · Class: 0.5%
- BVF Partners OS Ltd.
Shares: 30,882.00 · Class: 0.5%
- BVF GP HOLDINGS LLC
Shares: 601,225.00 · Class: 9.3%
- BVF PARTNERS L P/IL
Shares: 643,622.00 · Class: 9.99%
- BVF INC/IL
Shares: 643,622.00 · Class: 9.99%
- LAMPERT MARK N
Shares: 643,622.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-000479
- Form type
- SCHEDULE 13G/A
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership